These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32005706)

  • 1. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.
    Capozzi ME; Coch RW; Koech J; Astapova II; Wait JB; Encisco SE; Douros JD; El K; Finan B; Sloop KW; Herman MA; D'Alessio DA; Campbell JE
    Diabetes; 2020 May; 69(5):882-892. PubMed ID: 32005706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
    Saponaro C; Mühlemann M; Acosta-Montalvo A; Piron A; Gmyr V; Delalleau N; Moerman E; Thévenet J; Pasquetti G; Coddeville A; Cnop M; Kerr-Conte J; Staels B; Pattou F; Bonner C
    Diabetes; 2020 May; 69(5):902-914. PubMed ID: 31896553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
    Park JH; Seo I; Shim HM; Cho H
    J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
    Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
    Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
    Vergari E; Knudsen JG; Ramracheya R; Salehi A; Zhang Q; Adam J; Asterholm IW; Benrick A; Briant LJB; Chibalina MV; Gribble FM; Hamilton A; Hastoy B; Reimann F; Rorsman NJG; Spiliotis II; Tarasov A; Wu Y; Ashcroft FM; Rorsman P
    Nat Commun; 2019 Jan; 10(1):139. PubMed ID: 30635569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
    Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
    Hattersley AT; Thorens B
    N Engl J Med; 2015 Sep; 373(10):974-6. PubMed ID: 26332554
    [No Abstract]   [Full Text] [Related]  

  • 14. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
    Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
    Olgar Y; Turan B
    Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
    Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.
    Osataphan S; Macchi C; Singhal G; Chimene-Weiss J; Sales V; Kozuka C; Dreyfuss JM; Pan H; Tangcharoenpaisan Y; Morningstar J; Gerszten R; Patti ME
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No direct effect of SGLT2 activity on glucagon secretion.
    Kuhre RE; Ghiasi SM; Adriaenssens AE; Wewer Albrechtsen NJ; Andersen DB; Aivazidis A; Chen L; Mandrup-Poulsen T; Ørskov C; Gribble FM; Reimann F; Wierup N; Tyrberg B; Holst JJ
    Diabetologia; 2019 Jun; 62(6):1011-1023. PubMed ID: 30903205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.